The median price target on SQ stock calls for the company’s share price to move above $300 within the next 12 months. The company’s continued forays into cryptocurrency are also winning it new customers and praise from retail traders. The company’s goal is to “make Bitcoin custody more mainstream,” according to Square hardware lead Jesse Dorogusker. Analysts praised Square for moving into installment loans that are popular with people age 35 and younger.Īdditionally, Square has announced that it is building a Bitcoin hardware wallet. Wall Street’s reaction to the Afterpay deal was euphoric. After the deal is completed, customers will be able to manage these payments directly through Square’s equally-popular Cash App. They pay a fee only if they miss a payment. The deal should close in early 2022.Īfterpay allows its 16 million customers to pay for items in four interest-free installments. Its recent boost came after the company reported strong quarterly results and announced it is buying Australian fintech company Afterpay in a $29 billion all-stock deal. SQ stock has risen nearly 15% in the past month and is up 25% YTD to about $270 per share. The dip may even be a buying opportunity for investors.įinancial technology (fintech) company Square is another stock that can do no wrong lately.
But while the price has decreased considerably from its recent high, MRNA stock has several catalysts in its favor and is still on a bullish trend. The median price target on MRNA stock is $271.50 per share, which would imply a 29% decline from its current share price. However, its rise has also resulted in several recent downgrades by analysts who are screaming that it is now grossly overvalued. The company is also raising the price it charges for its Covid-19 inoculations.Īll of these factors have propelled Moderna’s stock higher. Additionally, clinical trials that show Moderna’s Covid-19 vaccine is effective against the highly contagious Delta variant of the respiratory disease. The stock’s recent addition to the S&P 500 index and stellar quarterly results have given it a boost. There appear to have been several catalysts for the mammoth gains in MRNA stock. In the past month, the company’s stock has risen about 65%. And despite a drop from its recent high, MRNA stock has shown few signs of slowing down. By comparison, the S&P 500 is up 18% through the first seven months of this year. That makes Moderna one of the best-performing stocks in the S&P 500 Index so far in 2021.
It reached a recent high above $480 per share and has since fallen to a price around $383. MRNA stock rose 96% in one month and is up more than 250% year-to-date (YTD). Boston-based biotech company Moderna has been a runaway train.
0 kommentar(er)
